Publications by authors named "Aying Wang"
Chimeric antigen receptor (CAR)-T cells encounter many issues when treating solid tumors, including tumor antigen heterogeneity and immunosuppression. United targeting of two tumor-associated antigens (TAAs) and blocking of PD-1 may solve this problem and enhance the function of CAR-T. Mucin 1 (MUC1) and prostate stem cell antigen (PSCA) are overexpressed in non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFArticle Synopsis
- CAR-T-cell immunotherapy shows great promise for blood cancers but struggles with solid tumors due to inefficient T-cell infiltration.
- Flap structure-specific endonuclease 1 (FEN1) plays a crucial role in DNA repair and is often overexpressed in cancer; inhibiting it may enhance cancer treatment.
- Combining FEN1 inhibitors like SC13 with CAR-T-cell therapy increases double-stranded DNA in tumor cells, which boosts chemokine secretion and helps CAR-T cells effectively infiltrate solid tumors, improving anti-tumor immunity.
Article Synopsis
- CAR-T cell immunotherapy has seen success in treating blood cancers, but is challenging for solid tumors due to difficulty in T cell infiltration and long-term immune response.
- Dendritic cells (DCs) can improve this by presenting tumor antigens and enhancing T cell infiltration, making the combination of DC vaccines and CAR-T therapy a promising treatment strategy for solid tumors.
- Research showed that DC vaccines boosted MSLN CAR-T cell proliferation, infiltration, and persistence in mouse models, suggesting a potential pathway for more effective CAR-T therapies in clinical settings.